{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:42:57Z","timestamp":1792183377685,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024J011322"],"award-info":[{"award-number":["2024J011322"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xops.2026.101269","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T05:29:57Z","timestamp":1780205397000},"page":"101269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase I\/II Study of NGGT001 Gene Therapy for Bietti Crystalline Dystrophy"],"prefix":"10.1016","volume":"6","author":[{"given":"Xiuju","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101269_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101377","article-title":"Unravelling CYP4V2: clinical features, genetic insights, pathogenic mechanisms and therapeutic strategies in Bietti crystalline corneoretinal dystrophy","volume":"107","author":"Jia","year":"2025","journal-title":"Prog Retinal Eye Res"},{"key":"10.1016\/j.xops.2026.101269_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00417-023-06178-y","article-title":"Clinical and genetic characterization of a large cohort of Chinese patients with Bietti crystalline retinopathy","volume":"262","author":"Li","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2026.101269_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1086\/383228","article-title":"Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2","volume":"74","author":"Li","year":"2004","journal-title":"A J Human Genet"},{"key":"10.1016\/j.xops.2026.101269_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/mol.112.080085","article-title":"CYP4V2 in Bietti\u2019s crystalline dystrophy: ocular localization, metabolism of \u03c9-3-polyunsaturated fatty acids, and functional deficit of the p. H331P variant","volume":"82","author":"Nakano","year":"2012","journal-title":"Molecul Pharmacol"},{"key":"10.1016\/j.xops.2026.101269_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/iovs.65.13.27","article-title":"Investigating microperimetric features in Bietti crystalline dystrophy patients: a cross-sectional longitudinal study in a large cohort","volume":"65","author":"Xu","year":"2024","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"10.1016\/j.xops.2026.101269_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mgg3.109","article-title":"Novel insights into the molecular pathogenesis of CYP 4V2-associated Bietti's retinal dystrophy","volume":"3","author":"Astuti","year":"2015","journal-title":"Molecul Genetics Genomic Med"},{"key":"10.1016\/j.xops.2026.101269_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41434-020-0159-3","article-title":"Treating Bietti crystalline dystrophy in a high-fat diet-exacerbated murine model using gene therapy","volume":"27","author":"Qu","year":"2020","journal-title":"Gene Therapy"},{"key":"10.1016\/j.xops.2026.101269_bib8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/gt.2008.66","article-title":"AAV-mediated gene therapy for retinal disorders: from mouse to man","volume":"15","author":"Buch","year":"2008","journal-title":"Gene therapy"},{"key":"10.1016\/j.xops.2026.101269_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-024-01806-3","article-title":"Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Therapy"},{"key":"10.1016\/j.xops.2026.101269_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamaophthalmol.2024.5619","article-title":"Safety and vision outcomes following gene therapy for Bietti crystalline dystrophy: a nonrandomized clinical trial","volume":"143","author":"Chen","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101269_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.xops.2026.101269_bib12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3390\/bioengineering12101122","article-title":"Surgical approaches to retinal gene therapy: 2025 update","volume":"12","author":"Patel","year":"2025","journal-title":"Bioengineering"},{"key":"10.1016\/j.xops.2026.101269_bib13","first-page":"429","article-title":"Two-port subretinal injection without vitrectomy for the treatment of Bietti crystalline dystrophy","volume":"40","author":"Luo","year":"2024","journal-title":"Chinese J Ocular Fund Diseases"},{"key":"10.1016\/j.xops.2026.101269_bib14","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-list-item national eye institute visual function questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Archiv Ophthalmol"},{"key":"10.1016\/j.xops.2026.101269_bib15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(24)00139-9","article-title":"Recommendations for accurate reporting in medical research statistics","volume":"403","author":"Mansournia","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101269_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/13816818609058037","article-title":"Bietti's crystalline retinopathy","volume":"7","author":"Yuzawa","year":"1986","journal-title":"Ophthal Paediatr Genet"},{"key":"10.1016\/j.xops.2026.101269_bib17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamaophthalmol.2024.5619","article-title":"Safety and vision outcomes following gene therapy for Bietti crystalline dystrophy: a nonrandomized clinical trial","volume":"143","author":"Chen","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101269_bib18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2022.06.006","article-title":"Adeno-associated virus serotype 2\u2013hCHM subretinal delivery to the macula in choroideremia: two-year interim results of an ongoing phase I\/II gene therapy trial","volume":"129","author":"Aleman","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101269_bib19","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"New England J Med"},{"key":"10.1016\/j.xops.2026.101269_bib20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.ymthe.2026.01.005","article-title":"Gene therapy for Bietti crystalline corneoretinal dystrophy: a phase 1\/2 clinical trial","volume":"34","author":"Yang","year":"2026","journal-title":"Molecul Therapy"},{"key":"10.1016\/j.xops.2026.101269_bib21","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101269_bib22","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/s41591-023-02520-3","article-title":"Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial","volume":"29","author":"MacLaren","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.xops.2026.101269_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ceo.13022","article-title":"Novel mobility test to assess functional vision in patients with inherited retinal dystrophies","volume":"46","author":"Chung","year":"2018","journal-title":"Clin Exper Ophthal"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:14:25Z","timestamp":1786954465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526002071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666914526002071"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101269","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I\/II Study of NGGT001 Gene Therapy for Bietti Crystalline Dystrophy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101269"}}